Chinese drug company Shenzhen Chipscreen Biosciences Co Ltd (SHA:688321) announced on Thursday that the Investigational New Drug (IND) application that it previously submitted to the Center for Drug Evaluation of National Medical Products Administration of China for CS231295 tablets, a Class 1 innovative drug for the treatment of tumours, has been accepted.

CS231295 is a novel brain-penetrating small-molecule, multi-target protein kinase inhibitor independently developed by Chipscreen Biosciences, with proprietary intellectual property rights. According to the company, this drug candidate exhibits significant synthetic lethal effects on tumours carrying particular genetic defects, providing a new treatment option for patients with such tumours.

CS231295 also demonstrates potent anti-tumour angiogenesis activity, resulting in wide-spectrum anti-tumour efficacy. In the future, CS231295, either as a monotherapy or in combination with other anti-tumour drugs, is expected to offer differentiated and innovative treatment options for various types of cancer.

In preclinical studies, the treatment has shown significant pharmacodynamic activity, favourable pharmacokinetic properties and a good safety profile.